IBSA Derma Virtual Congress, second edition27 November 2020
Following on from the success of the first edition, IBSA is launching a new edition of the virtual ‘IBSA DERMA’ congress. The Virtual Congress will entirely focus on the spearhead of the dermoaesthetic department product portfolio, PROFHILO®, retracing its history and the main stages that have led to its success in 72 countries around the world.
PROFHILO® is one of the hyaluronic acid treatments most favoured by doctors and most loved by patients. It was born in IBSA laboratories thanks to the innovative patented technology that allows the high and low molecular weight hyaluronic acid complex to be stabilised without any chemical agents added . PROFHILO® therefore has excellent biocompatibility. It is thanks to this technology that it is possible to offer greater concentrations of hyaluronic acid.
Maria Bisogni, Marketing & Communication Manager Dermoaesthetic Department at IBSA Farmaceutici, explains that “with the second edition of this virtual congress, IBSA Derma aims to offer specialists the chance to take part in live symposia with a group of international experts and speakers, getting to know one another and taking part in discussions with colleagues from all over the world. The aim is also to discover PROFHILO® at the virtual stands dedicated to this product, which is now recognised as a product that knows no bounds.”